ParAllele BioScience
Biosciences company enters collaboration to study genetics of heart disease
Published in Genetics and Environmental Business Week, November 4th, 2004
Coronary artery disease affects 13 million people in the United States and is the leading cause of death for both men and women. The results of the study will be used to identify biomarkers that can aid disease diagnosis and potentially guide treatment options, as well as identify and prioritize new drug targets.
In this Novartis-funded study, ParAllele will utilize its proprietary Mismatch Repair Detection (MRD) technology to comprehensively discover novel Single Nucleotide...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- Allergy Therapeutics
Pharmaceutical company raises GBP 16M, seeks admission to AIM - Biofrontera AG
Pharmaceutical firm secures an investment of EUR 20 million by DNAPrint - Broad Institute
NIH funds first national SNP genotyping center - GENETIX Pharmaceuticals, Inc.
Company raises $12 million to fund gene therapy - Radiation Therapy Services, Inc.
Radiation therapy services management company added to Russell Indexes - Targeted Genetics Corp.
Genetics products company named to Technology Fast 50 Program for Washington - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
